Background
==========

Human immunodeficiency Virus (HIV), Hepatitis B virus (HBV), and Hepatitis C virus (HCV), are the three most common chronic viral infections all over the world. They share similar transmission routes including sexual, blood-blood contact, and injecting drug usage \[[@B1],[@B2]\]. Co-infection with HIV and HCV and/or HBV is very common in certain populations, such as intravenous drug users (IDUs) who often share the contaminated needles/syringes for intravenous drug injection. It has been reported that the world prevalence of HIV-HCV co-infection among IDUs can surpass 90% in certain populations \[[@B3],[@B4]\]. Besides, the rates of HIV-HBV co-infection are reported as high as 10--20% in countries where HBV infection is either endemic or intermediate to high HBV cases \[[@B5]\]. It has been observed that HBV/HIV co infection leads to increased morbidity and mortality as compared to HIV or HBV mono-infections \[[@B5]\]. The ever increasing burden of these infections has become a growing concern \[[@B6]\]. With increased access to antiretroviral drugs for HIV patients, migrating populations and social networking by intravenous drug use, cases of HBV and HCV co infections have been on the rise \[[@B7]\], coupled with the dramatic rise in survival rates of these individuals \[[@B8]\]. As a result of these factors, cases of hepatic diseases have also been on the rise \[[@B9]\]. Studies show that HIV co infection adversely impacts on the natural history of HBV and HCV \[[@B7]\] by accelerating progression to chronic live disease due to drug-related hepatotoxicity and hepatitis reactivation \[[@B10]-[@B12]\]. At this stage, most patients are likely to die due to liver-related diseases compared to those without HIV infection \[[@B13]\].

In Kenya, the HIV-1 epidemic has been well documented. However, little data exists on HBV and HCV co infection among HIV-1 positive patients \[[@B14]\]. This study was carried out among HIV positive patients who were accessing CD4 testing services, to determine the levels of HBV and HCV co infections. This was done with the knowledge that such patients are at a high risk of a rapid disease progression coupled with development of liver cirrhosis and hepatocellular carcinoma \[[@B15]\].

Methods
=======

Between October and December 2009, a cross sectional study was carried out involving three (300) hundred consenting HIV-1 infected patients. The volunteers were recruited after providing written consent i.e. for persons aged above 18 years and assent from guardians and mothers of persons aged below 18 years. The enrolled volunteers were aged between 4--59 years of age. The participants were recruited through stratified sampling from nine Nairobi-based health centres namely; Baraka, Ngong, Pumwani, Ongata Rongai, Kangemi, Huruma, Kamiti, Ngaira and Waithaka. Blood was collected aseptically into 10 ml vacutainer tubes (Becton Dickson, New Jersey USA) for biochemical, CD4+ count and viral serology tests. The CD4+ T lymphocytes assay was performed within three hours of collection, while serum for serological assays for hepatitis C and B markers was stored at −20°C until the time for assay \[[@B16]\]. CD4+T lymphocytes count was determined by flow cytometry using Becton Dickson Facs calibur machine \[[@B17]\]. The determination of anti hepatitis C virus IgG antibody (anti HCV) and Hepatitis B antigen (HBsAg) were conducted by use of antibody capture ELISA, enzyme-linked immunosorbent assay kit (Hepanostika HBsAg) (Murex Biotech Ltd, Dartford, UK) \[[@B18]\] and Murex anti-HCV kit for Hepatitis C virus, (Murex anti-HCV version 4.0) \[[@B19]\]. HIV-1 and HIV-2 Vironostika HIV Uni-Form II Ag/Ab (Bio-Merieux, Boxtel, The Netherlands) following the manufacturer's instructions.

Ethical considerations
----------------------

This study was ethically approved by Kenya Medical Research Institute (KEMRI) National Scientific Steering Committee SCC reference no. 1394 before it was executed.

Data analysis
-------------

All generated data was entered into a database, cleaned and analyzed using SPSS version 11.5. The sero-prevalence for HBV and HCV were expressed as a percentage for the entire study group. Pearsons Chi square was used to test the association between level of immunosuppression and HBV/HCV infection. Simple linear correlation analysis was used to determine the association between age and HBV/HCV infection.

Results
=======

Three (300) hundred HIV patients comprising 129 (43%) males and 171 (57%) females were enrolled in this study. Their age ranged between 4--59 years with a mean age of 33.92 (±8.96) years with men 36.0 (±8.7) and 32.6 (±8.97) years for females (Table  [1](#T1){ref-type="table"}). There were 48 (16%) co-infections with 18 (56%) HIV/HBV, 30 (10.%) HIV/HCV, with 3 (1%) of those infected being detected with HIV/HBV/HCV coinfections. However, 248 (82.7%) were HIV monoinfected (see Table  [1](#T1){ref-type="table"}). In relation to gender, there was no difference in gender in dual infections of either HBV/HIV or HCV/HIV. However, males had the highest prevalence rates of HBV infection (55%) with females leading in HCV infections (53.3%). Among those infected, majority of them were aged 25 and 40 years (see Table  [2](#T2){ref-type="table"}). In addition, the mean CD4 counts in HBV/HIV co-infected patients were low compared to those either HCV/HIV co-infected patients or among HIV mono-infections (see Table  [1](#T1){ref-type="table"}).

###### 

Characteristics of HIV positive, HIV/HCV and HIV/HBV co-infected individuals

              **Categories**              **All n=(300)**     **Male**       **Female**     **HIV-1 only**   **HIV-1/HBV**   **HIV-1/HCV**    **HIV-1/HBV/HCV**   **p=value**
  -------------------------------------- ----------------- --------------- --------------- ---------------- --------------- ---------------- ------------------- -------------
          Age(yrs)\[mean (S.D)\]            33.9 (9.1)       35.7 (8.7)       32.6 (9)      34.24 (9.138)     34.8 (6.5)       30.6 (8.3)        33.3 (7.2)          0.001
   CD4+ T cell count (Cells/mm3) (Mean)    388 (±262.95)    375 (±250.2)    398 (±226.9)    400.7 (±270.1)       252.2       325.8 (±228.7)    576.7 (±213.5)        0.02
                 HBV (%)                                     10/18 (55%)     8/18 (45%)                                                                                 
                 HCV (%)                                    14/30 (46.7%)   16/30 (53.3%)                                                                               
            Patients \[n\] (%)               300 (100)       129 (43.0)       171 (57)        248 (82.7)        18 (6)          30 (10%)            3 (1)               

###### 

Prevalence of HIV-1, HBV, HCV coinfections by age and CD4+ counts

   **Age group**   **(n/300)**   **HIV**   **HBV/HCV**   **HBV**   **HCV**    **Average CD4 count**
  --------------- ------------- --------- ------------- --------- ---------- -----------------------
        1-5             2           2          \-          \-         \-              1211
       6-10             2           1          \-          \-         1                370
       11-15            2           2          \-          \-         \-               537
       16-20            4           3          \-          \-         1                409
       21-25           40          31           1           2         6                461
       26-30           73          61          \-           4      8 (11.1)            401
       31-35           61          52          \-           3         6                350
       36-40           48          35           2           5      6 (12.8)            356
       41-45           40          34          \-           4         2                380
       46-50           18          17          \-          \-         1                272
       51-55           10          10          \-          \-         \-               432
       56-60            3           3          \-          \-         \-               352
     **Total**       **300**     **248**      **3**      **18**     **31**               

Discussion
==========

With the increased access to antiretroviral therapy in resource limited settings, people living with HIV/AIDS will continue to live longer. However, morbidity and mortality due to co-infections with other viruses will increasingly become important. Although co infections with HBV and HCV among HIV positive patients is well documented in developing countries, the demographics and impact of these infections are not well defined in low resource countries like Kenya. The need for new data on hepatitis coinfections to guide health policy is on management of HIV coinfected a patient is paramount \[[@B19]\].

In this study, we examined the prevalence of HBV and HCV among HIV infected patients seeking CD4 testing services. From the results, it is clear that the co infection rates of HIV-infected patients with HBV and HCV was high (\>6%). This number is high even though the study participants were persons who were seeking CD4 testing services i.e. probably immunosuppressed and not representative of the general population. This has an indication that hepatitis infection in HIV-infected persons may be higher than that of the general population. Co --infection with HCV was also high (10%). This was higher than what we could expect in the general population i.e. about 5% \[[@B20],[@B21]\]. Compared to previous studies in Kenya on similar populations, these findings were contrarily higher 1.1% \[[@B22]\]; 0.7% \[[@B23]\], including those from Zambia (2.2%) \[[@B19]\], Cote d'voire (1.2%) \[[@B24]\], Gambia (0.6%) \[[@B25]\], Malawi (5.7%) \[[@B26],[@B27]\], Nigeria (4.8%) \[[@B28]\], Rwanda (4.9%) \[[@B29]\], Senegal (1.6%) \[[@B30]\] Uganda (0.6%) \[[@B31]\] and Zimbabwe (0.8%) \[[@B31]\] (Table  [3](#T3){ref-type="table"}). The higher rates could probably due to increased free access to antiretroviral therapy and diverse study subjects. However, the high estimate of HCV prevalence among HIV infected patients in this study were similar to those obtained in Tanzania; \[[@B21],[@B32]\] but less to those obtained in Argentina \[[@B33]\].

###### 

Surveys of hepatitis B virus surface antigen (HBsAg) and hepatitis C antibody (HCV Ab) prevalence in HIV-infected persons conducted in Kenya and neighboring sub-Saharan Africa countries, 1996-2013

                                   **Prevalence rates**                                                       
  -------------------------------- ---------------------- --------------- -------------- ------ ------ ------ -----
  Muriuki et al. (current study)   2013                   Kenya           Outpatient     300    6      10.3    
  Mutuma et al. \[[@B34]\]         2011                   Kenya           Outpatient     51     8.8            
  Kapembwa et al. \[[@B19]\]       2011                   Zambia          Inpatient      323    9.9    2.2     
  Moore et al. \[[@B26]\]          2010                   Malawi          Inpatient      300    6.7    5.7     
  Di Bisceglie et al. \[[@B35]\]   2010                   South Africa    Outpatient     502    4.8            
  Mboto et al. \[[@B25]\]          2010                   The Gambia      Outpatient     1500          0.6     
  Kerubo et al. \[[@B23]\]         2010                   Kenya           outpatients                  0.7    0.3
  Belay et al. \[[@B36]\]          2010                   Ethiopia        Blood donors   6321   4.7    0.7     
  Lukhwareni et al. \[[@B37]\]     2009                   South Africa    Outpatient     192    22.9           
  Oshitani et al. \[[@B38]\]       1996                   Zambia          Outpatient     340    7.1            
  Harania et al. \[[@B22]\]        2008                   Kenya           Outpatient     378    6.1    1.1     
  Nyirenda et al. \[[@B27]\]       2008                   Malawi          Inpatient      226    17.5   4.5     
  Otegbayo et al. \[[@B28]\]       2008                   Nigeria         Outpatient     1779   11.9   4.8     
  Diop-Niaye et al. \[[@B30]\]     2008                   Senegal         Outpatient     363    16.8   1.6     
  Shimeli et al. \[[@B39]\]        2008                   Ethiopia        Outpatient     305    3.9            
  Fimhaber et al. \[[@B35]\]       2008                   South Africa    Outpatient     502    4.8            
  Hoffmann et al. \[[@B40]\]       2008                   South Africa    Outpatient     537    19.7           
  Nagu et al. \[[@B20]\]           2008                   Tanzania        Outpatient     260    17.3   18.1    
  Pirillo et al. \[[@B29]\]        2007                   Uganda          Antenatal      164    4.9    0.6     
  Telatela et al. \[[@B32]\]       2007                   Tanzania        Outpatient            15     13.8    
  Lesi et al. \[[@B41]\]           2007                   Nigeria         outpatients    240    9.2    5.8    1.5
  Pirillo et al. \[[@B29]\]        2007                   Rwanda          antenatal      82     2.4    4.9     
  Wester et al. \[[@B42]\]         2006                   Botswana        Outpatient     160    10.6           
  Okoth et al. \[[@B43]\]          2006                   Kenya           Outpatient            15             
  Otedo et al. \[[@B44]\]          2004                   Kenya           Outpatient     599    47            53
  Ejele et al. \[[@B45]\]          2004                   Nigeria         outpatient     342    9.7           1
  Rouet et al. \[[@B24]\]          2004                   Cote d'Ivoire   Antenatal      501    9      1.2     
  Mustapha et al. \[[@B46]\]       2004                   Gombe Nigeria   outpatients    200    26.5           
  Kallestrup et al. \[[@B31]\]     2003                   Zimbabwe        Outpatient     124           0.8     
  Kasolo et al. \[[@B47]\]         2003                   Zambia          Antenatal      214    31.3           
  Ampofo et al. \[[@B42]\]         2002                   Nigeria         blood donors          15     8.4     
  Sud et al. \[[@B48]\]            2001                   Nigeria         outpatients    80     22.2           
  Lodenyo et al. \[[@B44]\]        2000                   South Africa    Outpatient     100    6      1       
  Rahlenbeck et al. \[[@B49]\]     1997                   Ethiopia        outpatients    2186   14.4           
  Oshitani et al. \[[@B38]\]       1996                   Zambia          Outpatient     340    7.1            
  Fainboim et al. \[[@B33]\]       1999                   Argentina       outpatients    484    14.5   58.5    

The HIV/HBV co infection rates (6%) detected in this study was found to be consistent with findings from other studies carried out in Kenya \[[@B22],[@B50]\], Zambia \[[@B19],[@B34]\], Cote d' Ivore \[[@B24]\], Malawi \[[@B25]\], Nigeria \[[@B38]\], Ethiopia \[[@B41]\] and South Africa \[[@B39]\]. However, these findings were low compared to those previous obtained in Kenya (55.8%) among liver failure patients \[[@B43],[@B44]\] Tanzania \[[@B32],[@B51]\], Zambia \[[@B47]\], Botswana \[[@B42]\], Malawi \[[@B27]\], Nigeria \[[@B28],[@B42],[@B46],[@B48]\], Ethiopia \[[@B40]\], Argentina \[[@B34]\] South Africa \[[@B37],[@B40]\] (Table  [3](#T3){ref-type="table"}). These prevalence rates were also found to be higher than those obtained in Ethiopia \[[@B35],[@B52]\], South Africa \[[@B35],[@B53]\], Uganda and Rwanda \[[@B29]\]. The observed diverse prevalence rates across different countries were associated with the diversity of patients from different population groups, sample size, test kit sensitivity and specificity \[[@B52]\].

The HIV co-infection rates as per gender in this study was found not to be significantly higher among male study subjects (19.2%) as compared to their female counterparts (14.3%) (p\>0.061). This finding was comparable to reports from elsewhere \[[@B22]\]. This observation may have been accounted for by the fact that men are more likely to have multiple sex partners and also practice unprotected sex due to the polygamous nature of their relationships.

We also observed a significant high prevalence in HCV antibody among HIV infected patients. The probable reason could be due to the shared modes of transmission of both viruses in the study patients. The prevalence of HIV/HCV was also found to be higher in Males (11.6%) as compared to females (9.4%). However, the difference was not significant (p\>0.055). This observation was similar to previous studies conducted in Kenya \[[@B23]\], Nigeria \[[@B4],[@B21]\] and contrarily to other findings of older females being more co- infected \[[@B23],[@B51]\].

Three patients (1%) were found co-infected with trio HIV, HBV and HCV infections in this study. These findings were similar to those obtained previously in Kenya \[[@B23],[@B25]\], Nigeria \[[@B53]\] and Ethiopia \[[@B29]\] indicating a maintained low rates of these trio infections \[[@B22],[@B23],[@B25],[@B35],[@B36]\] (Table  [3](#T3){ref-type="table"}).

Conclusions
===========

In spite of carrying out the study only among HIV-infected patients, it was evident that co-infection rates with HIV and HCV and/or HBV are higher among HIV infected individuals than populations that are HIV negative. There is therefore a need for constant surveillance of these infections that pose a challenge in vaccine design and treatment options.
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